Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
StrateGIST Legacy continued velzatinib treatment study in GIST
jRCT2031260580Phase 2Not yet recruiting
- Sponsor
- GSK
- Start
- Dec 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of IDRX-42 in gastrointestinal stromal tumor (GIST), sponsored by GSK. Primary endpoints: Number of participants with treatment-emergent adverse events and serious adverse events, Duration of treatment-emergent adverse events and serious adverse events and 3 more. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
IDRX-42
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on jRCT2031260580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260580.